Q4 2024 Earnings Call Transcript March 12, 2025 biote Corp. beats earnings expectations. Reported EPS is $0.1, expectations ...

Corp. (BTMD) delivered earnings and revenue surprises of 11.11% and 2.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

These updates follow the latest evidence-based medical literature and feature proprietary dosing algorithms that are unique in the marketplace. With these new algorithms, Biote-certified ...

Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth ...

personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging ...

IRVING, Texas, February 26, 2025--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone ...

Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...

In terms of the Zacks Industry Rank, Medical - Products is currently in ... Another stock from the same industry, biote Corp. (BTMD), has yet to report results for the quarter ended December ...